Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News CG Oncology Inc CGON

Healthcare Biotechnology
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3... see more

Current News (NDAQ:CGON)

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

GlobeNewswire February 27, 2026

CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

GlobeNewswire February 23, 2026

Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

GlobeNewswire January 14, 2026

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

GlobeNewswire January 9, 2026

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2026

SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

GlobeNewswire December 18, 2025

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

GlobeNewswire December 5, 2025

CG Oncology Announces New Board Member and Board Transition

GlobeNewswire November 26, 2025

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting

GlobeNewswire November 25, 2025
View More News ››

Opinion & Analysis (NDAQ:CGON)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CGON)

Be the first to post on this bullboard.

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc., an oil and natural gas company, engages in the acquisition, development, exploration, and production ...
View More »

Podcasts